Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

LLT Use in Patients with Elevated LDL-C

Circ Cardiovasc Qual Outcomes; ePub 2018 May 10; Virani, et al

Among patients with low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL, evidence-based lipid-lowering therapy (LLT) use remains low with significant variation in care, a new study found. Using data from the American College of Cardiology National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence registry, researchers assessed the proportion of patients with LDL-C ≥190 mg/dL (n=49,447) receiving statin, high intensity statin, LLT associated with ≥50% LDL-C lowering, ezetimibe, or a PCSK9 inhibitor between January 2013 and December 2016. Practice-level rates and variation in LLT use were also assessed. They found:

  • The proportion of patients receiving a statin, high-intensity statin, LLT associated with ≥50% LDL reduction, ezetimibe, or PCSK9 inhibitor were 58.5%, 31.9%, 34.6%, 8.5%, and 1.5%, respectively.
  • Median practice-level rates and adjusted median rate ratio (MRR) for statin (MRR, 1.20), high-intensity statin (MRR, 2.31), LLT with ≥50% LDL lowering (MRR, 2.12), ezetimibe (MRR, 2.42), and PCSK9 inhibitors (MRR, 2.38) indicated significant gaps and >200% variation in receipt of several of these medications for patients across practices.
  • Even larger treatment gaps were noted among those without concomitant ASCVD.

Citation:

Virani SS, Kennedy KF, Akeroyd JM, et al. Variation in lipid-lowering therapy use in patients with low-density lipoprotein cholesterol ≥190 mg/dL: Insights from the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. [Published online ahead of print May 10, 2018]. Circ Cardiovasc Qual Outcomes. doi:10.1161/CIRCOUTCOMES.118.004652.

This Week's Must Reads

Relevance of Health Literacy to CV Health, Circulation; ePub 2018 Jun 4; Magnani, et al

Can Biomarkers Predict Causes of Death in AF?, Circulation; ePub 2018 Jun 5; Sharma, et al

Aspirin Benefit in Adverse Pregnancy Outcomes, Hypertension; ePub 2018 May 25; Hauspurg, et al

Care for IHD and CHF Varies in VA Health System, JAMA Cardiol; ePub 2018 May 16; Groeneveld, et al

Comparing Hypertension Guidelines in CV Events, JAMA Cardiol; ePub 2018 May 23; Bundy, et al

Must Reads in Hypercholesterolemia

LLT Use in Patients with Elevated LDL-C, Circ Cardiovasc Qual Outcomes; ePub 2018 May 10; Virani, et al

Evolocumab in Differing Patient Populations , J Pharmacokinet Pharmacodyn; ePub 2018 May 7; Kuchimanchi, et al

LDL-C Targets in Elderly Statin Users After ACS, J Am Heart Assoc; ePub 2018 May 12; Alter, et al

Patient Perspectives on Statin Therapy, Clin Cardiol; ePub 2018 May 10; Brinton

Statin Use and Adverse Effects in Older Adults, J Am Heart Assoc; ePub 2018 May 8; Nanna, et al